Quick Answer
MADRIGAL PHARMACEUTICALS, INC. reported Operating Income Loss of -$300.10 million for the year ending 2025.
- MADRIGAL PHARMACEUTICALS, INC. showed an increase of +39.7% in Operating Income Loss from 2024 to 2025.
- This data is from MADRIGAL PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on February 19, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 17 years of available data (2009 to 2025), MADRIGAL PHARMACEUTICALS, INC.'s Operating Income Loss has declined by 478.4%.
- Historical annual values: Fiscal year 2025: -$300.10 million | Fiscal year 2024: -$497.88 million | Fiscal year 2023: -$380.50 million | Fiscal year 2022: -$293.57 million | Fiscal year 2021: -$242.48 million | Fiscal year 2020: -$206.67 million | Fiscal year 2019: -$94.97 million | Fiscal year 2018: -$40.68 million | Fiscal year 2017: -$32.06 million | Fiscal year 2016: -$25.22 million | Fiscal year 2015: -$3.23 million | Fiscal year 2014: -$83.95 million | Fiscal year 2013: -$87.56 million | Fiscal year 2012: -$60.94 million | Fiscal year 2011: -$45.43 million | Fiscal year 2010: -$36.90 million | Fiscal year 2009: $79.30 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: